What are your typical weekend reads? If you are a scientist, they might often include a great deal of science. I always hope I can find time for reading for pleasure too, but about as close as I get to that is the New York Times on Sunday. Here are some recommended science reads for […]
Weekend reads: stem cells, organoids, cancer, CRISPR & a tiger named Igor Read More »
Need a fix of some stem cell good news? I do. It has been a bumpy 2016 so far for the stem cell field and many challenges have popped up. So today at lunch and needing at least a short break from grant writing, I went looking for stem cell good news including interesting studies, promising
List of 11 stem cell good news or interesting stories Read More »
Editor’s note: this is a guest post on stem cell translation. By Heather Main I recently attended the UCSD Health CIRM Alpha Stem Cell Clinics Network Symposium at the Sanford Consortium, San Diego. There was of course some great academic research presented, including conflicting views on liver stem cell compartments from Roel Nusse and David
Keys to successful stem cell translation – Nurses, physicians and patient advocates Read More »
A lot has happened in 2014 in the stem cell and regenerative medicine field and so much of it has been good news so let’s focus on the positive. These positive developments are often the result of many years of creative, hard work by amazing teams of researchers. Here is my top 10 list of
Positive Stem Cell Developments in 2014 Read More »
The biotechs Vertex and CRISPR Therapeutics have an interesting relationship as biotechs. They are partners are multiple levels but also are very different as companies including in size. There’s been a key development in one of their partnerships. Before we jump into that, please check out the video version of my 20 stem cell and
Weekly reads: Vertex & CRISPR Therapeutics, Arnold Caplan death, MS genetics Read More »
Years ago I wrote about how I wished humans could form a blastema, which is a special area of regeneration near an injury that drives tissue replacement. For example, when a lizard loses its tail to a pursuing bobcat, if it can regrow a new one that process will depend on a blastema. The same goes
New Year’s reads: having a blastema, gene therapy cost, pathogen lab escape data Read More »
Let’s start this week’s digest with a discussion of clonal expansion and mutations during cell and gene therapy development. Here’s the article that brought this to mind. Sickle cell gene therapy process may cause cancer-linked mutations in blood stem cells, Fierce Biotech. Clonal expansion This is a story about a non-CRISPR gene therapy using a
Some folks can view data from early, small clinical trials too skeptically or overly enthusiastically, and maybe that’s going on with some preliminary results from Verve Therapeutics. Good news? Bad news? I’m going to start with two articles about the same news that have very different vibes. What do I think? On the whole, I
Weekly reads: Verve Therapeutics, Casgevy UK OK, GDNF, MYC Read More »
What’s more important than Woolly Mammoth de-extinction research in the stem cell arena? Only maybe a 10,000 other things. Still, the mammoth de-extinction efforts capture people’s attention much more than the average research story. Mammoth De-extinction update Is de-extinction only a pipette dream? This startup has a big, expensive plan to find out, Popular Science.
It’s been almost seventeen years that I’ve been a professor here at UC Davis Medical School. It feels like home. I enjoy teaching our first-year medical students each year. Some end up doing research in my lab. Our school recently got a nice write-up over at STAT News by Usha Lee McFarling on the diversity
Weekly reads: UC Davis Medical School diversity, CRISPR, Parkinson’s Read More »